Placed more than 350 AviClear devices during Q1 2023, and generated $4.4M in AviClear revenue in the quarter

Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2023.

First Quarter 2023 Financial and Operational Highlights

Consolidated revenue of $55.0 million, a decrease of 5% as reported and a decrease of 1% in constant currency from the prior-year period.
During Q1 2023, the Company generated $4.4 million in AviClear revenue, consisting of treatment revenue and device license fees.
AviClear placements exceeded 350 during Q1 2023, bringing cumulative placements to over 950 units.
GAAP Gross margin of 45.3% in the quarter, compared to 54.8% in the prior-year period.
- In constant currency terms, Q1 2023 GAAP Gross Margin was 47.4%, and non-GAAP Gross Margin was 51.0%
GAAP Operating expenses were $48.5 million in the quarter, compared to $44.9 million in the prior-year period. Operating expenses during the period included $10.1 million in AviClear spending.
GAAP Net loss was $25.0 million, compared to a Net loss of $15.1 million in the prior-year period.
Adjusted EBITDA was a loss of $14.5 million, compared to a loss of $3.8 million in the prior-year period.
- Core adjusted EBITDA was a loss of $8.5 million as reported and a loss of $6.8 million in constant currency.
- AviClear adjusted EBITDA was a loss of $6.0 million.

Three Months

Ended

March 31, 2023

% Change vs Three Months

Ended March 31, 2022

Three Months Ended

March 31, 2023

Key Revenue Metrics

Reported

Constant

Currency

Key Profit Metrics

Reported

Constant

Currency

Capital Equipment

$33.3

-9%

-6%

GAAP Margin %

45.3%

47.4%

Skincare

$8.1

-30%

-19%

Non-GAAP Margin %

49.1%

51.0%

Consumables

$3.7

-4%

-1%

Adjusted EBITDA - Core

($8.5)

($6.8)

Service

$5.4

-9%

-6%

Adjusted EBITDA - AviClear

($6.0)

($6.0)

AviClear

$4.4

N/A

Adjusted EBITDA - Total

($14.5)

($12.8)

Recurring

$21.7

Adjusted EBITDA Margin %

-26.4%

-22.1%

Total Revenue

$55.0

-5%

-1%

"First quarter performance was below expectations due to execution challenges in the business and certain operational events including an undue focus on AviClear placements that diverted attention from North America core capital sales, as well as an extended plant shutdown that affected sales and margin. However, even though it's been only a few weeks since I stepped into the Interim CEO role, it is clear to me that Cutera has great potential and that we can overcome our execution and operational challenges. I believe our core business continues to have great potential and I am especially encouraged by the placement of over 350 AviClear devices during Q1 2023, bringing cumulative placements to nearly 1,000 and highlighting the strong market acceptance of this revolutionary new offering for the treatment of acne," commented Sheila Hopkins, Interim Chief Executive Officer of Cutera, Inc.

Hopkins continued, "I remain excited about the future of Cutera and confident in our ability to improve our performance. We have technology and products that are excellent, differentiated, and well-liked by our customers, and we have a talented team that shares a strong commitment to our mission and a belief in the long-term vision for the business. As we look ahead, we believe our focus on improving execution will allow us to increase adoption and utilization of AviClear while driving growth in our core business."

CFO Transition

Cutera also announced the appointment of Stuart Drummond as Interim Chief Financial Officer, succeeding Rohan Seth, who has stepped down from the Company. Mr. Drummond brings over 20 years of experience leading and developing finance teams in the technology and manufacturing sectors. He joined Cutera in 2021 as Vice President and Corporate Controller and has been a senior leader of the finance team.

Hopkins added, "We appreciate Stuart's willingness to step up as Interim CFO and ensure continuity of leadership at such a critical time for our Company. Stuart knows our Company well, and we are fortunate to have someone of his caliber lead the finance team during this transitional period. A CFO search process has been underway as part of ongoing leadership planning and is being overseen by the Audit Committee of the Board and with the assistance of a leading executive search firm. We look forward to identifying the right candidate for the role."

Conference Call

The Company's management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Sheila Hopkins, Interim Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Greg Barker, Vice President of FP&A and Investor Relations.

To participate in the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4304 (international).

The call will also be a webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and operating income. Non-GAAP adjustments include stock-based compensation, depreciation and amortization including contract acquisition costs, executive and other non-recurring severance costs, enterprise resource planning ("ERP") implementation costs, and certain legal and litigation costs. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

The Company defines adjusted EBITDA as operating income before depreciation and amortization, stock-based compensation, executive and non-recurring severance costs, ERP implementation costs, and costs related to a specific litigation.

Company management uses non-GAAP measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Executive and other non-recurring severance costs. We have excluded costs associated with restructuring activities and the separation of our officers and other executives in calculating our non-GAAP operating expenses and non-GAAP Operating Income. We have excluded restructuring costs because a restructuring represents a discrete event that signifies a change in our strategy, but its costs are not indicative of the ongoing financial performance of our business. We exclude executive separation costs because executive separations are unpredictable and not part of our business strategy but could have a significant impact on the results of operation;

ERP implementation costs. We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance; and

Certain legal and litigation costs. We have excluded costs incurred related to our litigation against Lutronic Aesthetics, which is not part of our ordinary course of business. Our complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. We exclude these costs because this litigation is a result of a discrete event that was not part of our business strategy but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of our core operations.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include but are not limited to, Cutera's plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company's actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company's control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the first quarter ended March 31, 2023, as discussed in this release, is preliminary and unaudited, and subject to adjustment.


CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)


	March 31,			December 31,
	2023			2022
Assets
Current assets:
Cash and cash equivalents	$	166,828		$	145,924
Marketable securities		100,823			171,390
Accounts receivable, net		52,138			45,562
Inventories		71,819			63,628
Other current assets and prepaid expenses		26,156			24,036
Restricted cash		700			700
Total current assets		418,464			451,240

Property and equipment, net		53,016			40,368
Deferred tax asset		577			590
Goodwill		1,339			1,339
Operating lease right-of-use assets		12,059			12,831
Other long-term assets		14,343			14,620
Total assets	$	499,798		$	520,988

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	35,169		$	33,736
Accrued liabilities		58,660			57,452
Operating leases liabilities		2,722			2,810
Deferred revenue		12,243			11,841
Total current liabilities		108,794			105,839

Deferred revenue, net of current portion		1,643			1,657
Operating lease liabilities, net of current portion		10,652			11,352
Convertible notes, net of unamortized debt issuance costs		417,011			416,459
Other long-term liabilities		711			862
Total liabilities		538,811			536,169

Stockholders' equity:
Common stock		20			20
Additional paid-in capital		126,504			125,406
Accumulated other comprehensive loss		(8	)		(94	)
Accumulated deficit		(165,529	)		(140,513	)
Total stockholders' equity		(39,013	)		(15,181	)
Total liabilities and stockholders' equity	$	499,798		$	520,988

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)


	Three Months Ended
	March 31,			March 31,
	2023			2022

Products	$	49,588		$	52,066
Service		5,405			5,948
Total net revenue		54,993			58,014

Products		27,231			22,912
Service		2,835			3,314
Total cost of revenue		30,066			26,226
Gross margin		24,927			31,788
Gross margin %		45.3	%		54.8	%

Operating expenses:
Sales and marketing		29,512			24,944
Research and development		6,468			6,499
General and administrative		12,516			13,502
Total operating expenses		48,496			44,945

Loss income from operations		(23,569	)		(13,157	)
Interest and other expense, net
Interest on convertible notes		(2,939	)		(778	)
Amortization of debt issuance costs		(552	)		(219	)
Interest income (expense), net		2,479			(144	)
Other expense, net		(163	)		(611	)
Loss before income taxes		(24,744	)		(14,909	)
Income tax expense		272			233
Net loss	$	(25,016	)	$	(15,142	)

Net loss per share:
Basic	$	(1.26	)	$	(0.84	)
Diluted	$	(1.26	)	$	(0.84	)

Weighted-average number of shares used in per share calculations:
Basic		19,776			18,080
Diluted		19,776			18,080

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

	Three Months Ended
	March 31,			March 31,
	2023			2022
Cash flows from operating activities:
Net loss	$	(25,016	)	$	(15,142	)
Adjustments to reconcile net loss to net cash provided used in operating activities:
Stock-based compensation		3,386			4,043
Depreciation and amortization		1,409			427
Amortization of contract acquisition costs		2,178			652
Amortization of debt issuance costs		552			219
Deferred tax assets		13			41
Provision for credit losses		488			192
Loss on sale of property and equipment		-			14
Unrealized gain on foreign exchange forward		(623	)		-
Non-cash interest income		(880	)		-
Changes in assets and liabilities:
Accounts receivable		(7,064	)		(1,912	)
Inventories		(8,191	)		(12,177	)
Other current assets and prepaid expenses		(2,053	)		(5,611	)
Other long-term assets		(2,011	)		(385	)
Accounts payable		(1,330	)		5,755
Accrued liabilities		1,706			(5,989	)
Operating leases ,net		(16	)		30
Deferred revenue		388			239
Net cash used in operating activities		(37,064	)		(29,604	)

Cash flows from investing activities:
Acquisition of property, equipment and software		(11,153	)		(321	)
Purchase of marketable investments		(23,467	)		(74,058	)
Proceeds from maturities of marketable investments		95,000			-
Net provided by (used in) cash used in investing activities		60,380			(74,379	)

Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan		109			151
Taxes paid related to net share settlement of equity awards		(2,397	)		(2,450	)
Payments on capital lease obligation		(124	)		(150	)
Net cash used in financing activities		(2,412	)		(2,449	)

Net increase (decrease) in cash, cash equivalents and restricted cash		20,904			(106,432	)
Cash, cash equivalents, and restricted cash at beginning of period		146,624			164,864
Cash, cash equivalents, and restricted cash at end of period	$	167,528		$	58,432

CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)

	Three Months Ended						*% Change*
	March 31,			March 31,			*2023 Vs*
	2023			2022			*2022*
Revenue By Geography:
North America	$	27,669		$	28,853		-4.1	%
Japan		12,908			17,503		-26.3	%
Rest of World		14,416			11,658		+23.7	%
Total Net Revenue	$	54,993		$	58,014		-5.2	%
International as a percentage of total revenue		49.7	%		50.3	%

Revenue By Product Category:
Systems
- North America	$	17,959		$	22,707		-20.9	%
- Rest of World (including Japan)		15,358			13,807		+11.2	%
Total Systems		33,317			36,514		-8.8	%
AviClear		4,395			-		NA
Consumables		3,744			3,903		-4.1	%
Skincare		8,132			11,649		-30.2	%
Total Products		49,588			52,066		-4.8	%
Service		5,405			5,948		-9.1	%
Total Net Revenue	$	54,993		$	58,014		-5.2	%


	Three Months Ended
	March 31,		March 31,
	2023		2022
Pre-tax Stock-Based Compensation Expense:
Cost of revenue	$	364	$	459
Sales and marketing		1,148		576
Research and development		693		980
General and administrative		1,181		2,028
	$	3,386	$	4,043

CUTERA, INC.
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure
(in thousands)
(unaudited)

Three Months Ended March 31, 2023	Gross Profit		Gross Margin		Operating Income
Reported	$	24,927	45.3	%	$	(23,569	)
Adjustments:
Depreciation and amortization including contract acquisition costs		1,599	3.0	%		3,587
Stock-based compensation		364	0.6	%		3,386
ERP implementation cost		-	-			518
Legal - Lutronic		-	-			652
Severance		119	0.2	%		315
Other adjustments		-	-			585
Total adjustments		2,082	3.8	%		9,043
Adjusted	$	27,009	49.1	%	$	(14,526	)

Three Months Ended March 31, 2022	Gross Profit		Gross Margin		Operating Income
Reported	$	31,788	54.8	%	$	(13,157	)
Adjustments:
Depreciation and amortization including contract acquisition costs		76	0.1	%		1,079
Stock-based compensation		459	0.8	%		4,043
ERP implementation cost		-	-			3,976
Legal - Lutronic		-	-			254
Severance		-	-			-
Other adjustments		-	-			-
Total adjustments		535	0.9	%		9,352
Adjusted	$	32,323	55.7	%	$	(3,805	)

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005512/en/

Cutera Announces First Quarter 2023 Financial Results